Q-omics provides the consensus-scored ACTBP9 profile across patient tissues and cancer cell-line models. ACTBP9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ACTBP9 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, ACTBP9 RNA expression shows 11,650 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, BLCA, and THYM as cancer lineages where ACTBP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP9 survival associations across molecular data types. ACTBP9 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP9 RNA expression–survival associations across cancer types. High ACTBP9 expression shows unfavorable associations in MESO, PAAD, LGG and CHOL, but favorable associations in SKCM and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ACTBP9 RNA expression.
This table summarizes ACTBP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP9 shows lower tumor expression in BLCA, THCA, LIHC and CHOL and higher tumor expression in HNSC and BRCA. The BLCA box plot shows higher ACTBP9 RNA expression in normal versus tumor tissue (log2 FC = −0.290, t-test p = .009).
This table shows molecular features associated with ACTBP9 in patient tissues and cancer cell lines. In patient samples, ACTBP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
